InnerCap offers an advanced
patent-pending multi-phased,
multi-compartmentalized
capsular-based delivery
system. The system can be
used to enhance the value
and benefits of
pharmaceutical and
biopharmaceutical products.
Utilizing two-piece hard shell
capsules, the technology
offers the industry solutions
to problems affecting
pharmaceutical companies,
patients, and healthcare providers. The delivery system will be licensed to
enhance pharmaceutical and biopharmaceutical products. It is a very
effective way to deliver multiple active chemical compounds in different
physical phases with controlled-release profiles. The delivery system
provides the pharmaceutical and biopharmaceutical industries with
beneficial solutions to the industry’s highly publicized need to repackage
and reformulate existing patented blockbuster drugs with expiring patents
over the next 5 years. For more information, contact InnerCap
Technologies, Inc., at (813) 837-0796 or visit www.innercap.com.
KitoZyme offers KiOmedine, the first range of non-animal ultra-pure
chitosan and services for medical devices and drug delivery systems.
Manufactured from vegetal source and in accordance with cGMP,
KiOmedine ultra-pure chitosan exhibits excellent reproducibility, constant
quality totally independent of seasonal variations, traceability, no risk of
allergenicity, along with competitive price. KitoZyme’s product
development team (7-person staff of PhDs and engineers) provides
expertise in functionalization, processing, and formulation of biopolymers
applied to health sciences. KitoZyme also offers contract services, co-development opportunities, and capabilities to support customers in
bringing innovative products to the market in the fields of wound care,
haemostatics, surgical aids, ophtalmics, tissue engineering, drug delivery
systems, adjuvants for vaccination, or cell encapsulating material. For
more information, contact KitoZyme at info@kitozyme.com or visit
www.kitozyme.com.
Drug Delivery Technology June 2009 Vol 9 No 6
LCP is an emerging specialty
pharmaceutical company
focused on certain
cardiovascular indications and
organ transplantation. It
currently has one product on
the market, seven clinical
development programs
covering five product
candidates, and three product
candidates in preclinical
development. Its first
commercialized product, LCP-FenoChol, has received FDA
approval for sale in the US
under the brand name
Fenoglide TM and is marketed
in the US by Sciele Pharma.
Fenoglide and its other development compounds are based upon its
unique drug delivery technologies. The proprietary MeltDose® platform
enhances the absorption of poorly soluble drugs. Applying MeltDose
technology creates new versions of existing drugs with improved oral
bioavailability, improving efficacy, allowing for lower dose, and in some
cases, reducing food effect and/or potential side effects. For more
information, visit LCP at www.meltdose.com.
Mallinckrodt Baker recently launched PanExcea TM MHC300G
performance excipient, a homogeneous particle that serves as a filler,
binder, and disintegrant for immediate-release applications.
Manufactured using novel particle engineering technology, the
granular spherical excipient provides multifunctional performance
capabilities that enable efficient and cost-effective drug development
and manufacturing. PanExcea MHC300G lowers the total cost of
ownership for the drug formulator by facilitating direct compression
of even the most difficult APIs. It offers extensive API compatibility
and variable API load capability to increase formulation flexibility.
PanExcea MHC300G, which can be used as a building block or as a
complete excipient, provides formulation development flexibilities and
efficiencies, and enables implementation of Quality by Design (QbD)
initiatives. For more information, contact Mallinckrodt Baker at (800)
943-4747 or visit www.MallBaker.com/PanExcea.
